Alcon, the global leader in eye care dedicated to helping people see brilliantly, terminated its definitive merger agreement with STAAR Surgical Company announced on August 5, 2025.
“Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is unchanged and our new wavelight plus offering remains our focus for the most popular refractive surgery in the world, LASIK. This will be an exciting year for Alcon as we continue the global launches of more than 10 major products in both our surgical and vision care franchises. These innovations substantively advance outcomes for eye care disorders and help patients around the world see brilliantly,” said David J. Endicott, CEO of Alcon.